Napazimone is named as an intervention in 2 current clinical trials in our USA, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Czechia, UK and Australia registers. 2 are recruiting patients now. All registered phases are Phase 2. The lead sponsor is Pharming Technologies B.V. The most-studied condition is Primary Mitochondrial Disease.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease
NCT05650229 · ClinicalTrials.gov ↗ · Primary Mitochondrial Disease
|
Phase 2 | Recruiting | Pharming Technologies B.V | UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Czechia, Australia |
|
Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease
NCT07514338 · ClinicalTrials.gov ↗ · Mitochondrial Diseases
|
Phase 2 | Recruiting | Pharming Technologies B.V | USA, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Czechia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Pharming Technologies B.V | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our USA, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Czechia, UK and Australia registers name Napazimone (also registered as KL1333) as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in USA, 2 with sites in Germany, 2 with sites in France, 2 with sites in Spain, 2 with sites in Italy, 2 with sites in Netherlands, 2 with sites in Belgium, 2 with sites in Denmark, 2 with sites in Czechia, 1 with sites in UK and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Pharming Technologies B.V. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Napazimone works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Napazimone works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Napazimone (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.